Daily Archives: April 6, 2020
Non-alcoholic fatty liver is a risk factor for liver cancer
April 6th, 2020 Liver cancerNonalcoholic fatty liver disease (NAFLD) is a very common disease. To better understand the link between NAFLD and hepatocellular carcinoma (HCC) risk, researchers at Baylor College of Medicine conducted a large Retrospective study published in .... Read More
DNA testing can detect early liver cancer – Mayo clinic study
April 6th, 2020 Liver cancerResearchers at the Mayo Clinic in the United States reported at the 2018 Digestive Disease Week meeting that they have developed a DNA blood test that can correctly identify 95% of common liver cancer cases.At present, ultrasound and alpha-fetop.... Read More
Lovastinib for the treatment of first-line hepatocellular carcinoma
April 6th, 2020 Liver cancerBased on data from the REFLECT phase III trial, the US Food and Drug Administration (FDA) approved Lenvima as a first-line treatment for patients with unresectable hepatocellular carcinoma (HCC). The test was published in The Lancet in Febru.... Read More
A new drug in the treatment of liver cancer
April 6th, 2020 Drugs, Liver cancerA research team at the Cancer Research Institute (CSI) of the National University of Singapore has developed a novel peptide drug called FFW that may prevent the development of hepatocellular carcinoma (HCC) or primary liver cancer . This l.... Read More
Roche PD-1 inhibitor liver cancer combination therapy was recognized by the FDA as a breakthrough therapy
April 6th, 2020 Liver cancerThe Swiss Roche Group announced yesterday that TECENTRIQ® (atezolizumab) in combination with Avastin® (bevacizumab) has been approved by the US Food and Drug Administration (FDA) for breakthrough therapy for initial (first-line) treatment of a.... Read More
Cabozantinib prolongs progression-free survival for advanced liver cancer
April 6th, 2020 Liver cancerAccording to a study published in the New England Journal of Medicine published on July 5, Cabozantinib's overall and progression-free survival in patients with advanced hepatocellular carcinoma was significantly better than the placebo group.Dr.... Read More
Benefits of Ramucirumab for patients with high AFP liver cancer
April 6th, 2020 Liver cancerLiver cancerLiver cancer is a typical vascular-rich tumor, and tumor blood vessels play a very important role in the development of liver cancer. Therefore, the current targeted therapy of liver cancer is carried out around anti-angiogenesis. An.... Read More
Drug for thrombocytopenia
April 6th, 2020 DrugsDova Pharmaceuticals announced that the US FDA approved its subsidiary AkaRx's new drug Doptelet (avatrombopag) tablets for the treatment of low platelet counts (thrombocytopenia) in adults with chronic liver disease (CLD) who are scheduled to u.... Read More
Proton therapy for liver cancer is part of guidelines
April 6th, 2020 Liver cancerUN NCCN guidelines The US NCCN Clinical Practice Guidelines: Hepatobiliary Tumor (2018.V1) was updated on February 15, 2018. The latest version of the guideline uses proton therapy as one of the standard treatments for head and neck cancer. Nat.... Read More
New method to detect liver cancer biomarkers
April 6th, 2020 Liver cancerBecause liver cancer has many types, strong inheritance, and easy recurrence, identifying biomarkers that can predict disease progression is a key goal in fighting liver cancer.Recently, researchers have developed a method to identify the most c.... Read More